drugset / Trial / NCT00577629
Chemotherapy With Monoclonal Antibody and Radioimmunotherapy for High-Risk B-Cell Non-Hodgkins Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine whether using high-dose chemotherapy, monoclonal antibodies, and targeted radioimmunotherapy will slow the progression of disease in patients with high-risk Non-Hodgkin's Lymphoma (NHL).
Timeline
- Start
- 2005-06-18
- Primary completion
- 2012-04-08
- Completion
- 2016-11-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclophosphamide | Other / unclassified | 1.5 g | Intravenous |
| Subject | Cytarabine | Small molecule | 3 g | Intravenous |
| Subject | Doxorubicin | Other / unclassified | 45 mg/m2 | Intravenous |
| Subject | Etoposide | Small molecule | 300 mg/m2 | Intravenous |
| Subject | Rituximab | Monoclonal antibody | 375 mg/m2 | — |
| Subject | Tositumomab | Monoclonal antibody | 185 mbq | — |
| Subject | Tositumomab | Monoclonal antibody | 450 mg | — |